Cancer Overscreening High Among Older Adults

Overscreening for colorectal, cervical, and breast cancer is prevalent among older adults in the United States, according to the results of a new study. While routine cancer screening for adults with average cancer risk is recommended by the US Preventive Services Task Force (USPSTF), it is recommended that screening be discontinued once individuals reach a specified upper age limit, defined as age 75 for colorectal cancer, age 65 for cervical cancer, and age 74 for breast cancer. However, many ...
Continue reading

Hypertensive Medications and Reduced Colorectal Cancer Risk: Wai K. Leung, MD

In this interview, Wai K. Leung, MD, speaks with i3 Health about his research team's finding, recently published in Hypertension, that angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are associated with a decreased risk of colorectal cancer within three years of colonoscopy. Dr. Leung discusses the significance of the study's results and shares potential reasons behind the link between ACE inhibitor and ARB use and reduced colorectal cancer risk. Can you c...
Continue reading

Colorectal Cancer: Common Blood Pressure Medications May Reduce Risk

Taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is associated with a decreased risk of colorectal cancer within three years of colonoscopy, according to the results of a new study. By inhibiting or blocking angiotensin, a protein that raises blood pressure by constricting the arteries, ACE inhibitors and ARBs treat heart disease, heart failure, and high blood pressure. Whether ACE inhibitors and ARBs can also play a role in cancer prevention, howeve...
Continue reading

Family History-Based Colorectal Cancer Screening: Samir Gupta, MD

Colorectal cancer rates in younger adults are currently rising, and those with a family history of the disease face an even greater risk. Samir Gupta, MD, Chief of the Gastrointestinal (GI) Section of the San Diego Veterans Affairs Healthcare System, recently spoke with i3 Health about his research team's finding, now published in Cancer, that only 25% of patients between the ages of 40 to 49 who were diagnosed with colorectal cancer as a result of screening met the family history-based early sc...
Continue reading

Encorafenib/Cetuximab for BRAF V600E–Mutant Metastatic Colorectal Cancer: Scott Kopetz, MD, PhD, FACP

After patients with metastatic colorectal cancer who have a BRAF V600E mutation stop responding to first-line treatment, they have a median survival of only four to six months. These patients now have a new option in a combination therapy consisting of encorafenib (Braftovi®, Array BioPharma) and cetuximab (Erbitux®, Lilly), which was approved by the FDA earlier this month for adults with previously treated BRAF V600E-mutated metastatic colorectal cancer. In this interview with i3 Health, Scott ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.